Curing Better than Mother Nature
Our body is designed to balance our homeostasis throughout life. This life-long balance includes the scheduled, thus gene-programmed, moment of death. In the body, such homeostatic balance is carefully and constantly coordinated by the actions of agonists and antagonists. As we age, however, our body naturally experiences the deterioration of certain tissues and brain functions. This is a result of gene-programmed balancing acts, which we collectively call age-related disorders. Overcoming this natural gene-bound barrier is the clinical focus of darnatein.
Design-Augmented (DA) biologics are a new type of biotherapeutic drug that we believe can overcome this natural barrier. darnatein scientists designed DA biologics that perform better than their natural counterparts, often as agonists, to cure spine and joint disorders for a longer and healthier life. DaRT101 and DaRT102 are DA biologics. They work as a super-agonist of the TGF-beta/BMP signaling pathway.
Technically speaking, DA biologics are protein or RNA molecules. Their ‘designed’ sequences are derived from sequence modules of natural parental sequences. Such modules within the natural protein and RNA molecules have been re-ordered to create chimeric signals with improved clinical effects. Successes at darnatein include new TGF-beta related super-agonists, DaRT101 and DaRT102, which are currently being developed to cure spine and joint disorders. DA drugs, DaRT101 and DaRT102, have improved our clinical ability dramatically to regenerate fresh and young cells in the degenerated tissue.
We strive to deliver these new drugs to your bedside as soon as we can. Come dare with us to become the innovative tissue engineers at darnatein.